Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study - PubMed
6 hours ago
- #Lecanemab
- #Alzheimer's Disease
- #Real-World Evidence
- Real-world study of Japanese Alzheimer's patients treated with Lecanemab showed ARIA incidence at 20% (mostly asymptomatic), with 4% ARIA-E (all APOE ε4 carriers) and 16% isolated ARIA-H.
- Safety profile was manageable: 28% had mild infusion-related reactions, 16% discontinued treatment (mainly due to disease progression), and no symptomatic ARIA occurred.
- Exploratory analyses indicated trends linking ARIA risk to lower baseline MMSE scores, higher plasma GFAP levels, and higher deep white matter Fazekas scores, highlighting need for individualized risk assessment.